November 16, 2016
Across the United States, the high cost of hepatitis C (HCV) drugs means that patients often struggle to access life-saving treatment. State-level Medicaid programs are legally obligated to provide these drugs, but many programs find ways to deny treatment. The three more common tactics employed are liver damage (fibrosis) restrictions, prescriber restrictions and sobriety restrictions.
While restrictions vary state by state, restrictions eased somewhat across the country from 2014 to 2016, according to preliminary data presented at the Liver Meeting 2016, by Robert Greenwald, director, Center for Health Law and Policy Innovation at Harvard Law School, and Ryan Clary, executive director of the National Viral Hepatitis Roundtable. Greenwald presented the 2016 data as an update to his 2014 survey of state Medicaid policies.
Credit: zimmytws for iStock via Thinkstock.
Sony Salzman is a freelance journalist reporting on health care and medicine, who has won awards in both narrative writing and radio journalism. Follow Salzman on Twitter: @sonysalz.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Long-Acting HIV Treatment: 5 Myths and Realities|
|Two-Drug HIV Treatment Regimens Effective in Latest Studies|
|'Stop Describing, Start Intervening': Can the CDC's New Viral Load Data Help Guide HIV Programs?|
|The Need to Advocate for Fair HIV Drug Prices|
|Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity|
|Dose Reduction Potential of Nanoparticle ARV Formulations Confirmed in Humans|